FIGURE
FIGURE 3
- ID
- ZDB-FIG-210327-82
- Publication
- Chung et al., 2021 - Development of the CK-MB-1 trastuzumab-resistant HER2-positive breast cancer cell line and xenograft animal models
- Other Figures
- All Figure Page
- Back to All Figure Page
FIGURE 3
Antiproliferative effects of different drugs in three trastuzumab‐resistant cell lines. MDA‐MB‐453, HCC1954, and CK‐MB‐1 cells were treated with one anti‐HER2 monoclonal antibody, two chemotherapies, and five tyrosine kinase inhibitors targeting HER2, PI3K, or AKT. These drugs were less effective against the proliferation of CK‐MB‐1 cells than against the other two trastuzumab‐resistant cell lines. HER2, human epidermal growth factor receptor 2; PI3K, phosphoinositide‐3‐kinase |
Expression Data
Expression Detail
Antibody Labeling
Phenotype Data
Phenotype Detail
Acknowledgments
This image is the copyrighted work of the attributed author or publisher, and
ZFIN has permission only to display this image to its users.
Additional permissions should be obtained from the applicable author or publisher of the image.
Full text @ Cancer Med